Inc. (NASDAQ:INCR) Files An 8-K Results of Operations and Financial ConditionItem 2.02 Results of Operations and Financial Condition
Certain portions of our press release dated March 13, 2017, a copy of which is annexed hereto as Exhibit no. 99.1, are incorporated by reference herein, and are filed to this Item 2.02. They are as follows:
· The 1st paragraph relating to the announcement of the results of operations for the fourth quarter of 2016
· The 2nd paragraph relating to results of operations for the fourth quarter of 2016
· The 3rd, 7th and 8th paragraphs relating to results of operations for the full year 2016
· The 4th paragraph relating to European operations
· The 5th paragraph relating to United States operations
· The 9th paragraph relating to the Balmain brand
· The 10th paragraph relating to the Karl Lagerfeld brand
· The 11th paragraph relating to balance sheet items
· The 14th paragraph relating to the conference call to be held on March 13, 2017
· The consolidated statements of income and consolidated balance sheets
Item 7.01 Regulation FD Disclosure
Certain portions of our press release dated March 13, 2017, a copy of which is annexed hereto as Exhibit no. 99.1, are incorporated by reference herein, and are filed to this Item 7.01 and Regulation FD. They are as follows:
· The 6th paragraph relating to 2017 product launches
· The 12th paragraph relating to 2017 guidance
· The 16th paragraph relating to forward looking information
· The balance of such press release not otherwise incorporated by reference in Items 2.02 or 8.01
Item 8.01 Other Events
The 13th paragraph of our press release dated March 13, 2017 relating to our cash dividend is incorporated by reference herein.
Item 9.01 Financial Statements and Exhibits
99.1 Our press release dated March 13, 2017.
About Inc. (NASDAQ:INCR)
INC Research Holdings, Inc. is a global contract research organization (CRO). The Company is focused on Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. The Company operates through two segments: Clinical Development Services and Phase I Services. The Company’s Clinical Development Services segment offers all clinical development services, including full-service global studies, as well as ancillary services, such as clinical monitoring, investigator recruitment, patient recruitment, data management, study reports to assist customers with their drug development process, quality assurance audits and specialized consulting services. The Company’s Phase I Services segment focuses on clinical development services for Phase I trials, which include scientific exploratory medicine, first-in-human studies through proof-of-concept stages and support for Phase I studies in established compounds. Inc. (NASDAQ:INCR) Recent Trading Information
Inc. (NASDAQ:INCR) closed its last trading session down -0.25 at 45.30 with 720,833 shares trading hands.